These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 24582540)

  • 1. Personalized medicine for the management of benign prostatic hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Olumi AF
    J Urol; 2014 Jul; 192(1):16-23. PubMed ID: 24582540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Wang Z; Vangel MG; Wu CL; Tabatabaei S; Olumi AF
    J Urol; 2015 Oct; 194(4):1031-7. PubMed ID: 25916673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign prostatic hyperplasia progression and its impact on treatment.
    Djavan B; Waldert M; Ghawidel C; Marberger M
    Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New innovative therapies for benign prostatic hyperplasia: any advance?
    Klingler HC
    Curr Opin Urol; 2003 Jan; 13(1):11-5. PubMed ID: 12490810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
    McVary KT; Rogers T; Mahon J; Gupta NK
    J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
    Dedhia RC; Calhoun E; McVary KT
    J Urol; 2008 Jan; 179(1):220-5. PubMed ID: 18001791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.
    Homma Y; Gotoh M; Kawauchi A; Kojima Y; Masumori N; Nagai A; Saitoh T; Sakai H; Takahashi S; Ukimura O; Yamanishi T; Yokoyama O; Yoshida M; Maeda K
    Int J Urol; 2017 Oct; 24(10):716-729. PubMed ID: 28748576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathophysiology and therapy of benign prostatic hyperplasia].
    Sampson N; Madersbacher S; Berger P
    Wien Klin Wochenschr; 2008; 120(13-14):390-401. PubMed ID: 18726663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.